About Riddhima Chakraborty

Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries.

Recent Articles By Riddhima Chakraborty

: AMGN |  News, Ratings, and Charts

4 Biotech Stocks to Keep an Eye on in 2023

The U.S. 2022 fourth-quarter GDP growth surpassed estimates and induced fresh optimism. On the other hand, the biotech industry is expected to witness robust demand despite macro uncertainties. So, given the stable prospects of the biotech sector, quality stocks Amgen (AMGN), BioNTech (BNTX), Exelixis (EXEL), and Taisho Pharmaceutical (TAIPY) could be worth keeping an eye on in 2023. Keep reading...
: BBBY |  News, Ratings, and Charts

Is BBBY Still a Stock to Sell in 2023?

While Bed Bath & Beyond (BBBY) has been gaining traction lately, Wall Street analysts see a potential downside of nearly 60% in the near term. Moreover, the company recently initiated its latest round of layoffs. So, is BBBY still not worth buying? Let’s find out...
: HUM |  News, Ratings, and Charts

3 Health Care Stocks to Buy During Times of Uncertainty

The healthcare industry usually holds up well in times of uncertainty, thanks to the inelastic demand for their products and services. As macroeconomic uncertainties related to the high inflation and a potential recession remain, quality stocks Humana (HUM), NextGen Healthcare (NXGN), and InfuSystem (INFU) might be ideal buys now. Keep reading...
: ARC |  News, Ratings, and Charts

2 Penny Stocks to Add to Your Portfolio in 2023

Odds of the Fed slowing down on its rate hike aggression have been rising amid cooling inflationary pressures. Moreover, experts now see chances of the economy avoiding a recession. Therefore, investors might consider buying quality penny stocks ARC Document (ARC) and Rave Restaurant (RAVE) in 2023. Keep reading...
: ABEV |  News, Ratings, and Charts

3 Dirt-Cheap Stocks to Buy Right Now

Amid easing inflation numbers, the Fed is expected to slow down its rate hike aggression in 2023. Moreover, the stock market might witness a recovery this year. Given the favorable outlook, investors should consider buying dirt-cheap yet quality stocks Ambev (ABEV), VEON (VEON), and Cidara Therapeutics (CDTX) in 2023. Keep reading...
: CSCO |  News, Ratings, and Charts

The #1 Stock to Buy for 2023

Cisco (CSCO) surpassed revenue estimates by more than $300 million in its last reported quarter. Despite the broad market sell-off, it has gained 6% over the past six months. Moreover, Wall Street analysts see an upside potential of nearly 17% for the near term. Therefore, CSCO might be a quality stock to own in 2023. Let’s discuss this in detail…
: CVS |  News, Ratings, and Charts

3 Strong Buy Stocks With Major Upside Potential in 2023

Despite mass layoffs, the U.S. economy looks resilient enough to avoid a recession. Moreover, consumer sentiment remains pretty robust. Therefore, investors could consider buying quality stocks CVS Health (CVS), McKesson (MCK), and Archer-Daniels-Midland (ADM), which look poised to soar this year. Keep reading...
: DOCU |  News, Ratings, and Charts

Is This SaaS Stock Worth Buying for Under $55?

SaaS stock DocuSign (DOCU) reported steady top-line growth in its last reported quarter. However, it has lost more than 57% over the past year and is currently trading under $55. Moreover, with its bottom line in the red, will it be wise to buy DOCU now? Let’s find out...
: UMC |  News, Ratings, and Charts

The 3 Best Stocks to Buy With $20

The declining inflation, expected slower rate hikes, and a tight labor market are raising hopes of the economy achieving a soft landing. Moreover, the stock market is expected to recover this year. Therefore, investors could consider buying quality stocks United Microelectronics (UMC), Yext (YEXT), and Xperi (XPER), which are currently trading under $20. Keep reading…
: V |  News, Ratings, and Charts

Is Visa a Stock to Buy in 2023?

Visa’s (V) top and bottom line witnessed more than 20% year-over-year growth in the last fiscal year despite the macro uncertainties. The stock has delivered steady returns over the past months. Moreover, Wall Street analysts see a more than 12% upside potential in the stock. So, let’s find out whether you should invest in the stock now…

Page generated in 1.1962 seconds.